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Primary care genomic research: one eye on the future 
The exceptional advances in genomic medicine in the last two decades, since the 
sequencing of the human genome, have already had a major impact on healthcare in the 
UK. Until recently this was predominantly in secondary and tertiary care but we must now 
integrate “mainstream” genomics in primary care. So far integration has of necessity been 
empirical but must progress towards implementation research. We describe recent work 
undertaken by the RCGP and the NIHR CRN outlining areas where research is needed to fully 
integrate genomics into routine primary care and secure the future of these exciting 
developments.  
 
Clinical case scenario 
A 42-year-old man attends an NHS health check with a healthcare assistant (HCA) which 
includes a blood test for HbA1c, lipid profile and genomic profiling for cardiovascular 
disease (CVD) risk. During the consultation the HCA asks about his family history of CVD, 
including first- and second-degree relatives, and records this in the electronic health 
record (EHR). The patient then has a follow-up phone consultation with his GP who uses a 
current version of QRISK to generate a Polygenic Risk Score (PRS) for CVD over the next 10 
years. Data regarding genomic variants are extracted and incorporated with other data 
including smoking and family history. The patient’s PRS is above the threshold for offering 
primary prevention with a statin, and he asks if the genomic test is ‘the one to see if 
statins won’t agree with me’. The GP explains that this genomic test only identifies 
variants which influence his CVD risk; however, he knows that the practice is recruiting 
patients for a research study aiming to evaluate pharmacogenomic testing delivered by 





Since the publication of the ‘Generation Genome’ 2016 Annual Report by the Chief Medical 
Officer Dame Sally Davies in 2017, there has been a burgeoning increase in the integration 
of genomic medicine into UK clinical care (Davies, 2017). Large-scale healthcare 
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reorganisation has already commenced, with the creation of a new nationally commissioned 
Genomic Medicine Service (GMS) supported by seven Genomic Laboratory Hubs, soon to be 
overtaken by the new GMS Alliances. These initiatives have all arisen from the 
internationally renowned 100,000 Genomes project, focusing on genomic testing for 
patients with cancer, infectious diseases and as yet undiagnosed rare disorders including 
developmental disorders (Turnbull et al., 2018). The 100,000 Genomes Project has also 
supported a large number of empirical research studies further developing our 
understanding of pathological variants in the context of these disorders. This whole 
initiative has been led by NHS England (NHS England, 2016a). 
Clinicians in secondary and tertiary care, particularly in oncology, are now experienced at 
using genomic variation as the basis for a personalised approach to assessing risk for 
individual cancers and cancer subtypes. This fits with the desire to promote personalised 
medicine- “the right drug, at the right dose, to the right patient, at the right time”- and with 
NHS England’s “4Ps” programme of promoting individualised or personalised medicine in all 
aspects of healthcare (NHS England, 2016b). It is likely, as some commentators suggest, that 
the whole taxonomy of medicine will change as the genomic basis of disease becomes 
clearer. We are already seeing examples of this in diabetes, for example, where genomic 
subtypes of diabetes have been suggested, with different phenotypes, clear genotypic 
differences and very different disease trajectories (Ahlqvist et al., 2018). However, in other 
subtypes of diabetes such as maturity onset diabetes of the young (MODY) the genomic 
basis is much clearer with genomic mutations affecting the potassium channel now 
prompting urgent changes of treatment for diabetes ( (Delvecchio et al., 2020). 
 
The patient perspective on genomic testing has become extremely important of late, 
particularly when direct-to-consumer (DTC) testing has flourished (Horton et al., 2019). GPs 
can expect to see increasing requests from patients to advise on their DTC genomic results, 
which may prove a challenge to most primary care professionals. The RCGP and British 
Society of Genetic Medicine (BSGM) have recently produced helpful advice on DTC testing 
(RCGP, 2019). As the genomic revolution in healthcare moves away from patients referred 
into secondary and tertiary care towards primary care, it is clear that there are a large 
number of unanswered questions. A recent Lancet commentary (Manolio et al., 2019), 
identified three main challenges for genomic medicine implementation which will need to 
be addressed (Box 1). 
Box 1 HERE  
As the need for implementation of genomic medicine in primary care has become more 
apparent, a number of key educational and implementation initiatives have been led by the 
RCGP and Health Education England. It is against this background that the RCGP and the 
Clinical Research Network (CRN) of the National Institute of Health Research (NIHR) came 
together. The aim was to identify and define the key building blocks that were needed in 
primary care to establish a research evidence-base in primary care to facilitate the delivery 
of genomic medicine. 
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In 2018 the RCGP and the CRN engaged in a collaborative process led through Cluster C of 
the CRN, based in King’s College, London. This process was supported by key stakeholders 
and national leaders in genomics as well as front-line clinicians in primary care and 
representatives from a number of the 15 local Clinical Research Networks (CRNs) across 
England.  
Following initial meetings, and on the advice of the Steering Group, it became clear that 
there were three main areas or workstreams that needed further exploration, namely, 
informatics and family history taking, education of GPs and primary care staff, and 
operationalising genomic research. For each of these key workstreams a meeting was held 
with stakeholders and individuals with an interest in that area. A number of 
recommendations were identified to further facilitate effective primary care research in 
genomics (RCGP and NIHR CRN, 2018).     
 
Challenges  
Informatics and family history recording 
During the consultation process the stakeholders identified one of the biggest barriers to 
effective primary care genomics research in the NHS to be the lack of standardised family 
history recording in the primary care electronic health records (EHRs). Furthermore, there 
were major difficulties with recording of specific genomic variants in the EHR. 
For many decades now, GPs have known the importance of family history in the health of 
the patient (Qureshi et al., 2012) and acknowledged its relevance to family practice across 
the world (Vorderstrasse et al., 2013) (Walter and Emery, 2012). However, the level and 
quality of family history recording in GP records, both in the UK and abroad, is poor (Dhiman 
et al., 2014) (Wilson et al., 2009) and is inadequate to provide reliable disease risk 
assessments. This is despite various approaches and attempts to develop short family 
history tools (Walter et al., 2013) (Emery et al., 2014) and evidence of their successful 
implementation in routine clinical practice (Qureshi et al., 2012). 
In the recent Lancet series on genomic medicine Ginsburg and colleagues (Ginsburg et al., 
2019) confirmed that family history “is (the) most useful means of assessing risk for 
common chronic diseases” and was often underused for actionable risk assessment. In their 
opinion, family history remains the gold standard for risk assessment and advances in 
personalised medicine must align with improvements in family history recording. 
Importantly, they recognised that family history reporting, particularly in a primary care 
context, identifies multiple aspects of disease risk, including environmental, molecular and 
social. The 2018 RCGP/CRN report proposes a practical approach to clinical genetics and 
genomics for primary care, acknowledging the importance of systematic family history 
recording for disease risk assessment to underpin the recruitment and stratification of 
patients into research studies. 
Many studies have shown that there is not yet an optimal tool for family history recording in 
primary care with issues around digital data collection and storage, updating and 
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confidentiality (De Hoog et al., 2014). However, there have been a number of recent 
disease-specific UK research innovations in primary care risk assessment tools. The FAMCAT 
clinical case-finding algorithm has been developed and evaluated to identify patients with 
familial hypercholesterolaemia in primary care (Weng et al., 2018). The CanRisk Tool (Archer 
et al., 2020) incorporates the new version of BOADICEA, the Breast and Ovarian Analysis of 
Disease Incidence and Carrier Estimation Algorithm, into a tool for use in primary care and 
in genetics clinics (Lee et al., 2019).  
To optimise use, these and other disease risk assessment tools ideally need to be integrated 
into the clinical system operated by the GP software suppliers with an associated Clinical 
Decision Support System (Chase et al., 2017). The tool itself would need to be associated 
with new educational resources for primary care staff to enable optimal recording of family 
history, risk assessment and tailored management including evidence-based 
communication. 
Other information technology issues raised by the group included the need to facilitate 
better recording of detailed information, for example single gene variants, which would 
assist in the diagnosis of disorders with a genomic basis. This may be facilitated by the 
imminent move from Read codes to SNOMED codes in GP systems. Additionally, there will 
be a need to record pharmacogenomic variants (see below) as the impact of genomics on 
prescribing in a primary care setting could increase exponentially in the near future. 
Another issue that affects both primary and secondary care genomics is the recording of 
family members’ diseases in the medical record of the patient who is the case. Ironically, 
although GPs are family doctors and used to dealing with families, there may be uncertainty 
about recording family history in the family members’ records, for reasons of medical 
confidentiality coupled with the fact that patients can now access their own medical records 
and could inadvertently see the FH of family members.  
One solution to this is to use the household function which is available in some GP clinical 
systems and is designed for administrative purposes. However, patients living at the same 
address may not be in the same family. In the 100,000 Genomes project some hospitals 
have instituted a family number to assist with this. Clear guidance does exist (Royal College 
of Physicians, Royal College of Pathologists and British Society for Genetic Medicine, 2019) 




In order to facilitate effective primary care genomic research, the stakeholders recognised 
the need for genomics education crosscutting both of the other workstreams. Appropriate 
education of healthcare professionals is generic to all initiatives in primary care and 
genomics research is no different. The HEE’s Genomics Education Programme (GEP) has 
already started to identify the key knowledge (in particular knowledge updates) and skills 
required by GPs in this area. This will apply to both GPs with and without an extended role 
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in primary care genomics. This work has been conducted in the context of a wider 
educational needs assessment for genomics in primary care. 
This has included a multidisciplinary Delphi-style survey carried out by HEE GEP in 2017 
aimed to identify knowledge, skills and attitudes required by GPs in the genomics era. The 
themes identified broadly fell into 3 categories:   
 
• Knowledge, Skill and Attitudes (KSA) which were core to General Practice. These 
include communication skills and risk communication and are captured in the RCGP 
core curriculum document 
• Pre-existing KSA in genetics which are generalisable, e.g. family history assessment 
and reproductive health options 
• Novel KSA to the genomics era, e.g. understanding of NHS GMS, eligibility for 
genomic tests, and ability to communicate genomic information, as well as some 
novel ethical issues in and around data 
 
The RCGP (2019) have produced a genomics toolkit with a section that includes helpful 
resources to help educate primary care staff engaged in genomics research. A grounding in 
genomic education is particularly important in the research context where it is likely that 
GPs and their teams may be consenting patients to participate in genomic studies and 
likewise may be feeding back the results of genomic tests. Both aspects of this research 
activity need an appropriate level of genomic understanding and of the implications of 
positive/negative genomic testing, in whatever context the study is placed.  
The report recommended that the NIHR CRN develop specific training addressing these 
issues around genomic research and that study-specific educational material would help 
deliver genomic studies moving forward. This would build on the excellent work already 
undertaken by the NIHR CRN in the wider context of stratified medicine studies and 
resources developed to underpin that initiative (Attar et al., 2019). 
 
Operationalising NIHR genomic research in primary care  
The stakeholder group agreed that genomic studies are not completely similar to studies of 
therapeutic interventions or drug treatment. The complexity of genomic testing, coupled 
with the implications for the patient and their family, adds another dimension to a primary 
care research study recruiting through general practices or pharmacies. An example of a 
study that recruited from General Practice and the NIHR-CRN was the BARCODE study, 
looking at targeted genetic profiling for prostate cancer (Case Medical Research, 2019)   
This workstream considered a number of similar case studies from primary care genomic 
research already underway and identified key issues around the taking and storage of 
genomic specimens, the cost of genomic testing and recording results from research studies 
in the EHR. The group also noted that study teams would need to provide more education 
to practices undertaking genomic research. This could be in the form of ‘academic detailing’ 




The Report recommended that the CRN costing processes are refined; case studies of 
successful CRN genomic research studies are developed to both promote research and 
identify key learning from other studies; CRN staff facilitating genomic studies should have a 
good understanding of genomics, and finally that the associated paperwork should be 
minimal. 
 
Current areas of activity in primary care genomic research 
The NIHR CRN recently (November 2019) invited the leading UK academics in primary care 
genomic research to a Clinical Studies Group to identify their current areas of interest and 
research activity. The following areas were identified as the current strengths: 
Pharmacogenomics 
The role of genomic variants in determining the best way to individualise drug therapy is 
increasingly recognised, although the evidence-base for clinical utility in a primary care 
setting has not yet been demonstrated, nor has the cost-effectiveness. A recent Lancet 
paper (Roden et al., 2019) is a helpful summary of the current state of play but also 
identifies a number of potential barriers to implementation, some of which have been 
mentioned previously, such as the current EHR systems and the challenges of cost-
effectiveness. Another recent qualitative paper also explores these issues (Rafi et al, 2020). 
 
Rare diseases 
Work in the 100,000 Genomes project showed the clinical utility of genomic testing in rare 
diseases, including confirming a diagnosis, establishing prognosis, potentially changing 
treatment and enabling accurate genetic counselling for the family. In the Deciphering 
Developmental Disorders (DDD) study an extra 10% of patients received a definitive 
diagnosis through a genomic-driven approach (Fitzgerald et al, 2015). It is often not 
recognised that patients with rare disease constitute one in 17 of the GP population 
(Department of Health, 2013) and GPs have a positive role to play in the diagnosis, 
management and referral of these patients, including the use of appropriate genomic 
testing. 
Building on the excellent work undertaken by the 100,000 Genomes project, there is now a 
move to undertake further research in primary care using large GP databases to determine 
phenotypic information that could potentially identify those patients in practices with rare 
diseases. This could build on tools developed through artificial intelligence, machine 
learning and predictive modelling. Although this is in its infancy, the potential in this area is 
exceptional, building on the renowned strengths of the primary care GP clinical database in 
the UK (Saunders et al., 2020). There are also linked initiatives to identify phenotypic and 
genotypic information that could be used to identify high-risk individuals in whom adverse 
reactions to medication could be predicted with greater certainty. 
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Polygenic risk scores  
There has been a rapid proliferation of polygenic risk score reports, particularly those used 
in the context of common chronic diseases in primary care such as diabetes, CVD, 
depression and psychiatric disorders. GPs are used to working with predictive risk tools and 
communicating risk to patients, but the additional benefit of these tools above and beyond 
existing risk calculators will need to be clarified in further research. The PHG foundation 
published an excellent review of polygenic risk scores in 2019 (PHG, 2019).  
Family history and risk prediction tools 
A number of UK primary care academic centres are engaged in developing, testing and 
researching the implementation of integrated disease risk assessment tools, for example to 
facilitate the early diagnosis of Familial Hyperlipidaemia in Nottingham (Weng et al., 2015) 
and inherited cancers in Cambridge (Lee et al., 2019).  
Risk stratification in cancer  
The BARCODE study (Case Medical Research, 2019), led by the Institute for Cancer Research 
in London, has recruited from primary care and is investigating using genetic and genomic 
profiling to stratify men for targeted population screening for prostate cancer. Following a 
pilot study, a larger study is recruiting 5000 men aged between 55 and 69. The NIHR CRN 
has successfully facilitated recruitment.     
 
The future 
It is clear that there are a large number of research studies to be undertaken and the NIHR 
CRN is adapting to facilitate these studies as they come onto the CRN portfolio. As new 
genetic mutations and genomic variants are identified, it is vital that they are incorporated 
into approaches that provide personalised screening, early detection, diagnosis, 
management and prescribing and that validation is undertaken in a primary care setting. 
Perhaps the greatest research needed moving forward is for implementation research. 
Possible research questions include: how best should genomic medicine be embedded 
within primary care, what is the optimum model for referral and cost-effectiveness, and 
how best to engage primary care teams with new knowledge needed to deliver personalised 
medicine?  
The NHS Long Term Plan (NHS Improvement, 2019) is explicit in its support for genomic 
implementation and genomic research in the NHS. The 2018 RCGP/CRN Report 
recommended that funding bodies such as UKRI and the NIHR consider the need for funding 
of high-quality implementation studies around genomic initiatives in primary care as a 
matter of priority in the next few years. 
As well as the need for better genomic education medical school and postgraduate training 
in general practice to empower the future workforce, there is also a need for GP registrars 
and early career GPs to be provided with opportunities to pursue an academic career in 
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primary care genomic research. This could be part of the extensive career development and 
support funding that is provided by the NIHR Academy Fellowship Programme for all stages 




Recent developments in genetics and genomics are certain to impact on primary care as the 
pace of change continues to accelerate. There is therefore an urgent need for multi-faceted 
research studies to determine the evidence-base that is needed to ensure successful 
implementation of genomic medicine in a primary care setting. 
 
 
Key Points:  
• The integration of genomics into routine primary care needs an understanding of 
how to use genomics in a personalised approach to management of patients, 
including new treatments and a new infrastructure now led by the nationally 
commissioned Genomic Medicine Service  
• Integration is being helped, informed and promoted by the Royal College of General 
Practitioners (RCGP), the Genomics Education Programme and Health Education 
England’s online genomics resources 
• Integration is being informed and helped by research into informatics, education and 
operationalising genomic research in primary care as identified by the RCGP and the 
National Institute of Health Research Clinical Research Network  
• Integration will involve recognition that a genomic result may have implications for 
all family members, whether or not they need screening; if possible the GP should 
work with the whole family as well as the individual  
• Primary care-based genomic research is needed to provide the evidence base, 
including clinical utility and cost-effectiveness which will underpin the use of 
genomics in primary care 
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Box 1 - Pharmacogenomic issues. 
Discovery research 
This includes assessing genotype-phenotype associations, characterising pathogenic variants 
and identifying patients at higher risk of disease due to their genomic variation. 
 
Clinical validation  
This includes research to identify the effects of genomic information on health outcomes 
and the clinical utility of genomic testing in various clinical scenarios. Clinical utility is an 
important concept in this context and is defined as “the relevance and usefulness of an 
intervention in patient care” (Lesko et al., 2010). In primary care this is multi-dimensional, 
involving physical, psychological and social dimensions. 
 
Clinical implementation 
How best to embed routine genomic testing in clinical care, what information technology 
systems are needed to support this and how best to educate healthcare professionals and 
patients? 
 
Source: Manolio et al., 2019 
 
